Abstract: A method for treating intestinal fibrosis in a subject, comprising enterally administering a steroid to the subject. The steroid may be in a multiple minibead formulation.

Abstract: The present invention provides a perfuming composition that is free of ethanol and that is in the form of a transparent, clear microemulsion that contains a fragrance at a concentration of 0.5 to 50% by weight; a solvent at a concentration of 1 to 36% by weight; a non-ionic surfactant at a concentration of 1 to 35% by weight; an ionic surfactant at a concentration of 0 to 12% by weight, a cooling hydrotrope at a concentration of 0.01 to 12% by weight and water. Said microemulsions benefit from the presence of a cooling hydrotrope which allows lowering the amount of surfactant needed and provides a cooling effect.

Abstract: A method for concealing vitiligo is provided. The method comprises depressing a spring head. The spring head may be covered by a covering. Depression of the spring head may saturate the covering with a solution. The solution may include a bronzer and dihydroxyacetone (“DHA”). The method may also comprise guiding the saturated covering over a portion of depigmented skin.

Abstract: The purpose of the present invention is to provide a specific wound healing accelerator effective for accelerating healing of wounds, particularly of wounds in the oral cavity, or a composition which includes the wound healing accelerator. This wound healing accelerator including a specific polyphenol is easy to handle and is capable of accelerating would healing even by contact for a short time.

Abstract: In a multilamellar liposome, a pharmaceutical agent is encapsulated in the liposome in the absence of a partition enhancing buffer. Preferably, the pharmaceutical agent is prostaglandin E1 (PGE1). The pharmaceutical agent may be administered to a mammal in an amount effective to treat vascular disease. The release of the pharmaceutical agent from the multilamellar liposome may be regulated by proper selection of liposome size, dosage of the pharmaceutical agent, lipid to pharmaceutical agent weight ratio, and rate of infusion of the pharmaceutical agent.

Abstract: The present invention relates to a novel use of fucosterol and, more specifically, to a composition for skin whitening or composition for skin moisturizing, which is characterized by containing fucosterol. Fucosterol of chemical formula 1 below has an excellent whitening effect of inhibiting melanin generation and tyrosinase activity, and thus can be used as an active ingredient of a cosmetic composition for whitening, a food composition, or a pharmaceutical composition.

Abstract: The invention relates to an antimicrobial barrier device and methods of manufacture. The antimicrobial barrier comprises one or more antimicrobial drugs that inhibit biofilm formation and bacterial and/or fungal growth. The antimicrobial barrier is suited for use with insertable devices (e.g., catheters) to reduce the incidence of infection at and around the insertion site.

Abstract: The present invention discloses an integrin receptor targeting novel cationic CGKRK-lipopeptide. The present invention further discloses a liposomal formulation comprising the cationic CGKRK-lipopeptide, at least two co-lipids, at least one chemotherapeutic agent and a pharmaceutically acceptable carrier. The present invention also provides a method for regressing established tumors comprising administering therapeutically effective amount of the liposomal formulation comprising the chemotherapeutic agent.

Abstract: A method of treating neoplasia in a subject in need of treatment is provided by administering to the subject an amount of a prodrug of mitomycin C that yields a therapeutically effective amount of mitomycin C, in combination with radiation therapy. In one embodiment, the prodrug of mitomycin C is a liposomal-prodrug of mitomycin C. Together, the prodrug of mitomycin C and radiation therapy provide a synergistic antineoplastic effect.

Abstract: Nutritional compositions that mimic whole foods and methods of using the nutritional compositions are provided. The nutritional compositions may include an increased number and variety of fruits and vegetables, an increased variety of macronutrient sources and an increased amount of other components that are found in whole foods. The nutritional compositions may also include ethnicity-specific meals and organic ingredients and provide emotional appeal to the patient and/or the patient's caregiver. Methods of administering such nutritional compositions to patients in need of same are also provided.

Abstract: A composition for treating inflammation and pain, including a hydrogen-generating compound in an amount that increases the amount of hydrogen in an individual and has an anti-inflammatory effect. A composition for treating inflammation and pain, including synergistically effective amounts of pregabalin and lactulose. A method of treating inflammation and pain, by administering a composition comprising a hydrogen-generating compound to an individual in an amount that increases the amount of hydrogen in the individual and has an anti-inflammatory effect.

Abstract: Crystalline micronized particulate of a glycopyrronium salt may be prepared by hydrodynamic cavitation. The resulting drug particles are physically stable with regard to agglomeration and/or aggregation on storage.

Abstract: Compositions and pharmaceutical compositions including one or more selenium-containing COX-2 inhibitors are provided according to aspects of the present invention. Methods of treating a subject having or suspected of having cancer are provided according to aspects of the present invention which include administering a therapeutically effective amount of a pharmaceutical composition including a selenium-containing COX-2 inhibitor.

Abstract: Certain embodiments described herein are directed to cohesive materials comprising treated, derivatized collagen molecules. In some embodiments, the cohesive material can function as a putty or defect filler that can be used in a tissue repair. Methods of using the cohesive materials are also described.

Abstract: Docetaxel and doxorubicin can be formulated in liposomal pharmaceutical compositions. In various embodiments, the pharmaceutical compositions include (i) a first liposome type comprising a first lipid layer comprising an unsaturated phospholipid, cholesterol or a cholesterol derivative, DC-cholesterol, a cationic lipid, and preferably a pegylated phospholipid, and a first active pharmaceutical ingredient (API) comprising docetaxel in the first lipid layer; and (ii) a second liposome type comprising a second lipid layer, an aqueous interior, and a second API comprising doxorubicin crystallized in the aqueous interior, (iii) where the first liposome type does not comprise doxorubicin and the second liposome type does not comprise docetaxel. The pharmaceutical composition can be used to treat a subject, for example, a human subject having cancer.

Abstract: Combination therapies for treating cancer comprising administration of a topoisomerase-1 inhibitor and a PARP inhibitor are provided. The topoisomerase-1 inhibitor can be delivered as a liposomal formulation that provides for prolonged accumulation of the topoisomerase-1 inhibitor within a tumor relative to outside of the tumor. Therapeutic benefit can thereby be obtained by delaying the administration of the PARP inhibitor after each administration of a liposomal irinotecan formulation until the accumulation of the topoisomerase inhibitor in the tumor is sufficiently greater than outside the tumor to result in increased efficacy of the PARP inhibitor and topoisomerase inhibitor within the tumor, while reducing the peripheral toxicity of the combination therapy. The therapies disclosed herein are useful in the treatment of human cancers with solid tumors, including cervical cancer.

Abstract: Oral care compositions comprising: (a) a peroxide complex comprising a peroxide component and an N-vinyl heterocyclic polymer (e.g., poly-N-vinyl polylactam, or poly-N-vinyl-polyimide); (b) a whitening agent (e.g., hydrogen peroxide); and (c) an orally acceptable carrier. In one embodiment, the carrier comprises a film forming material. Methods are also provided for making an oral care composition comprising: (a) mixing a whitening agent, silicone adhesive and carrier fluid to form a homogenous mixture; (b) adding a peroxide complex to said homogenous mixture, wherein said complex comprises hydrogen peroxide and an N-vinyl heterocyclic polymer; and (c) mixing under vacuum.

Abstract: An object of the present invention is to provide an agent that potentiates the antitumor effect of an anticancer agent by allowing efficient accumulation of the anticancer agent in tumor tissue. The administration of carbonate apatite with the anticancer agent allows efficient accumulation of the anticancer agent in the tumor tissue to dramatically potentiate the antitumor effect of the anticancer agent.

Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.

Abstract: Methods of preparing sterile de-cellularized human amniotic fluid that is amenable for long-term storage without loss of biological functions have been developed. In particular, the methods involve refrigeration steps to maximize shelf-life while retaining most of the important growth factors and other molecules present in the fresh amniotic fluid for effective therapeutic application. Use of the compositions is intended for therapeutic purposes and will alleviate pain or discomfort associated with any disorders or diseases, particularly those involving eyes and joints, or fibrotic disorders such as COPD.